FOXO TECHNOLOGIES INC. Material Event - What Happened

This report explains the latest news regarding FOXO Technologies in plain English, helping you understand what is happening with your investment.

1. What happened?

FOXO Technologies, a biotech company focused on epigenetic research, recently changed its top financial leadership. On March 18, 2026, Chief Financial Officer (CFO) Sylwia Nowak Hauman resigned. After a short transition, the company appointed Celene Laurene Rattray Grant as the new CFO on March 24, 2026.

2. Why did it happen?

This change stems from a disagreement over how the company is run. When she resigned, Ms. Hauman told the Board of Directors she was concerned about the company’s internal financial controls. Specifically, she noted that the finance department lacked the staff and resources needed to ensure accurate, timely reporting to the SEC.

FOXO’s management team disagreed. They stated that the company’s financial controls are strong and that the team has enough resources to meet public reporting requirements. Management described the departure as a strategic move, insisting their current financial setup supports the company’s operations.

3. Why does this matter?

When a CFO resigns citing "internal controls," investors should pay close attention. Internal controls are the checks and balances—like data verification and audit trails—that prevent financial errors or fraud. A public argument over these controls suggests the company might struggle to report its finances accurately. This is vital for a company like FOXO, which relies on investor money to fund its research.

The company hired Celene Grant to address these concerns. Her background in financial restructuring suggests the company wants to fix any weaknesses in its reporting framework.

4. Who is affected?

• Investors: Shareholders may face more price swings. FOXO is a speculative biotech company, and its value depends on investor confidence. Public fights between executives and the finance team often lead to more short-selling and falling stock prices.
• The Company’s Reputation: FOXO must stay in good standing with the SEC. Any instability in the finance department makes it harder to raise money or secure partnerships, as stakeholders require total transparency to manage their own risks.

5. What happens next?

The company must soon file its Form 10-K, its comprehensive annual report. This will be the first major test for the new CFO. Investors should check this report for any "material weaknesses" noted by auditors. A clean, on-time filing could help stabilize the stock. A delay or a negative opinion from auditors would confirm the former CFO’s concerns.

6. What should investors know?

• Watch the 10-K: Look at "Item 9A: Controls and Procedures." This section states whether management and auditors believe the company’s financial controls are effective.
• Be cautious: The company’s defense is a standard way to protect its reputation. Rely on the objective data in the 10-K rather than press releases.
• Check your risk: FOXO is currently high-risk. Leadership turnover and disputes over financial integrity increase the chance of regulatory issues. Because the company is speculative, ensure your investment size matches the risk of potential delisting or further instability.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.